Ocular Therapeutix Inc
NASDAQ:OCUL
Ocular Therapeutix Inc
NASDAQ:OCUL
Price:
6.015 USD
-4.37%
Market Closed
Updated:
May 21, 2024
Ocular Therapeutix Inc
Interest Income Expense
|
Ocular Therapeutix Inc
Interest Income Expense Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Ocular Therapeutix Inc
NASDAQ:OCUL
|
Interest Income Expense
-$10.1m
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-41%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Interest Income Expense
$212m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Interest Income Expense
-$676m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Interest Income Expense
$1.5B
|
CAGR 3-Years
130%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Interest Income Expense
-$1.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-13%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Interest Income Expense
-$368m
|
CAGR 3-Years
-133%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-30%
|
See Also
What is Ocular Therapeutix Inc's Interest Income Expense?
Interest Income Expense
-10.1m
USD
-10.1m
USD
Based on the financial report for Mar 31, 2024, Ocular Therapeutix Inc's Interest Income Expense amounts to -10.1m USD.
What is Ocular Therapeutix Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-41%
-41%
Over the last year, the Interest Income Expense growth was -84%. The average annual Interest Income Expense growth rates for Ocular Therapeutix Inc have been 46% over the past three years , and -41% over the past ten years .
You don't have any saved screeners yet
